Literature DB >> 15827160

Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.

Mingzhu Zhu1, J Andrew Bristol, Yuefeng Xie, Mervat Mina, Hong Ji, Suzanne Forry-Schaudies, David L Ennist.   

Abstract

Historically, the adenoviral E3 region was found to be nonessential for viral replication in vitro. In addition, adenoviruses whose genome was more than approximately 105% the size of the native genome were inefficiently packaged. These profound observations were used experimentally to insert transgenes into the adenoviral backbone. More recently, however, the reintroduction of the E3 region into oncolytic adenoviruses has been found to positively influence antitumor efficacy in preclinical models and clinical trials. In the studies reported here, the granulocyte-macrophage colony-stimulating factor (GM-CSF) cDNA sequence has been substituted for the E3-gp19 gene in oncolytic adenoviruses that otherwise retained the E3 region. Five viruses that differed slightly in the method of transgene insertion were generated and compared to Ar6pAE2fGmF (E2F/GM/DeltaE3), a previously described E3-deleted oncolytic adenovirus encoding GM-CSF. In all of the viruses, the human E2F-1 promoter regulated E1A expression and GM-CSF expression was under the control of the adenoviral E3 promoter and the packaging signal was relocated immediately upstream from the right terminal repeat. The E3-gp19-deleted viruses had similar cytolytic properties, as measured in vitro by cytotoxicity assays, but differed markedly in their capacity to express and secrete GM-CSF. Ar15pAE2fGmF (E2F/GM/E3b), the virus that produced the highest levels of GM-CSF and retained the native GM-CSF leader sequence, was selected for further analysis. The E2F/GM/E3b and E2F/GM/DeltaE3 viruses exhibited similar cytotoxic activity and GM-CSF production in several tumor cell lines in vitro. However, when compared in vivo in nude mouse xenograft tumor models, E2F/GM/E3b spread through tumors to a greater extent, resulted in higher peak GM-CSF and total exposure levels in both tumor and serum, and was more efficacious than the E3-deleted virus. Using the matched WI-38 (parental) and WI-38-VA13 (simian virus 40 large T antigen transformed) cell pair, GM-CSF was shown to be selectively produced in cells expressing high levels of E2F, indicating that the tumor-selective E2F promoter controlled E1A and GM-CSF expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827160      PMCID: PMC1082742          DOI: 10.1128/JVI.79.9.5455-5465.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Multigene expression from a replicating adenovirus using native viral promoters.

Authors:  Maxine Bauzon; Daniel Castro; Michael Karr; Lynda K Hawkins; Terry W Hermiston
Journal:  Mol Ther       Date:  2003-04       Impact factor: 11.454

2.  Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction.

Authors:  R M Horton; Z L Cai; S N Ho; L R Pease
Journal:  Biotechniques       Date:  1990-05       Impact factor: 1.993

3.  Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance.

Authors:  M Andersson; S Pääbo; T Nilsson; P A Peterson
Journal:  Cell       Date:  1985-11       Impact factor: 41.582

4.  An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens.

Authors:  H G Burgert; S Kvist
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbred animals.

Authors:  Waithaka Mwangi; Wendy C Brown; Harris A Lewin; Chris J Howard; Jayne C Hope; Timothy V Baszler; Patrick Caplazi; Jeffrey Abbott; Guy H Palmer
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

6.  In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

Authors:  J Andrew Bristol; Mingzhu Zhu; Hong Ji; Mervat Mina; Yuefeng Xie; Lori Clarke; Suzanne Forry-Schaudies; David L Ennist
Journal:  Mol Ther       Date:  2003-06       Impact factor: 11.454

7.  Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points.

Authors:  Harald Sauthoff; Jing Hu; Cielo Maca; Michael Goldman; Sheila Heitner; Herman Yee; Teona Pipiya; William N Rom; John G Hay
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

8.  A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.

Authors:  Thomas Wirth; Lars Zender; Bernd Schulte; Bettina Mundt; Ruben Plentz; Karl Lenhard Rudolph; Michael Manns; Stefan Kubicka; Florian Kühnel
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

Review 9.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

10.  Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1979-07       Impact factor: 41.582

View more
  4 in total

1.  Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.

Authors:  Z Zhai; Z Wang; S Fu; J Lu; F Wang; R Li; H Zhang; S Li; Z Hou; H Wang; R Rodriguez
Journal:  Gene Ther       Date:  2012-01-05       Impact factor: 5.250

Review 2.  "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Authors:  Balveen Kaur; Timothy P Cripe; E Antonio Chiocca
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

Review 3.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

4.  INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Authors:  B Ying; K Toth; J F Spencer; J Meyer; A E Tollefson; D Patra; D Dhar; E V Shashkova; M Kuppuswamy; K Doronin; M A Thomas; L A Zumstein; W S M Wold; D L Lichtenstein
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.